Drug intelligence / Profile preview

Diamond Shruumz

Development stage
Discontinued
Lead developer
Prophet Premium Blends
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Diamond Shruumz is a brand of edible products—including chocolate bars, gummies, and cones—marketed as "microdose" or psychedelic mushroom-infused edibles. These products have been found to contain a combination of psychoactive and pharmacologically active substances, including 4-acetoxy-N,N-dimethyltryptamine (4-acetoxy-DMT, also known as O-acetylpsilocin or psilacetin), psilocin (a Schedule I-controlled substance), muscimol (a compound from Amanita mushrooms), ibotenic acid, pregabalin (a prescription drug), and kavalactones such as desmethoxyyangonin, dihydrokavain, and kavain. The mechanism of action involves serotonergic hallucinogenic activity via 4-acetoxy-DMT/psilocin at serotonin receptors; GABAergic effects from muscimol; gabapentinoid activity from pregabalin; and additional CNS effects from kavalactones. The products have been linked to severe adverse health events including seizures, loss of consciousness, respiratory failure, abnormal heart rates/blood pressure, hallucinations, agitation/confusion, nausea/vomiting/abdominal pain. As a result of these findings and associated illnesses—including hospitalizations and deaths—the FDA has issued recalls for all Diamond Shruumz products[1][2][4][5].

Brand names
Diamond Shruumz
02

Targets

HTR2A (Serotonin receptor 5-HT2A)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on Diamond Shruumz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamond Shruumz.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call